
|Videos|November 26, 2013
The Treatment of Hairy Cell Leukemia
Author(s)Jae Park, MD
Jae Park, MD, attending physician, Leukemia Service, Memorial Sloan-Kettering Cancer Center, comments on the treatment of patients with hairy cell leukemia.
Advertisement
Clinical Pearls
Jae Park, MD, attending physician, Leukemia Service, Memorial Sloan-Kettering Cancer Center, comments on the treatment of patients with hairy cell leukemia.
- Patients with hairy cell leukemia typically receive cladribine or pentostatin and experience a long remission
- Patients are able to respond again to cladribine or pentostatin following relapse
- There are limited options for those who have gone through many lines of therapy
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
3
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5



















